Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $1.98 billion. The enterprise value is $1.70 billion.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 111.19 million shares outstanding. The number of shares has increased by 38.81% in one year.
| Current Share Class | 111.19M |
| Shares Outstanding | 111.19M |
| Shares Change (YoY) | +38.81% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 6.73% |
| Owned by Institutions (%) | 86.65% |
| Float | 83.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.23 |
| P/TBV Ratio | 7.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.85 |
| Quick Ratio | 17.53 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.26% and return on invested capital (ROIC) is -41.34%.
| Return on Equity (ROE) | -63.26% |
| Return on Assets (ROA) | -38.79% |
| Return on Invested Capital (ROIC) | -41.34% |
| Return on Capital Employed (ROCE) | -57.37% |
| Weighted Average Cost of Capital (WACC) | 3.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.10M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $46,000 in taxes.
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +184.19% in the last 52 weeks. The beta is -0.16, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | +184.19% |
| 50-Day Moving Average | 15.19 |
| 200-Day Moving Average | 14.23 |
| Relative Strength Index (RSI) | 73.34 |
| Average Volume (20 Days) | 1,671,290 |
Short Selling Information
The latest short interest is 14.96 million, so 13.45% of the outstanding shares have been sold short.
| Short Interest | 14.96M |
| Short Previous Month | 14.51M |
| Short % of Shares Out | 13.45% |
| Short % of Float | 17.91% |
| Short Ratio (days to cover) | 13.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | -95.90M |
| Operating Income | -159.27M |
| Pretax Income | -150.07M |
| Net Income | -150.11M |
| EBITDA | -158.80M |
| EBIT | -159.27M |
| Earnings Per Share (EPS) | -$1.49 |
Full Income StatementBalance Sheet
The company has $279.77 million in cash and $5.63 million in debt, giving a net cash position of $274.14 million or $2.47 per share.
| Cash & Cash Equivalents | 279.77M |
| Total Debt | 5.63M |
| Net Cash | 274.14M |
| Net Cash Per Share | $2.47 |
| Equity (Book Value) | 273.16M |
| Book Value Per Share | 2.46 |
| Working Capital | 269.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$120.40 million and capital expenditures -$127,000, giving a free cash flow of -$120.53 million.
| Operating Cash Flow | -120.40M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 467,000 |
| Net Borrowing | 190.74M |
| Free Cash Flow | -120.53M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |